258 related articles for article (PubMed ID: 35164900)
21. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
22. Hsp90: still a viable target in prostate cancer.
Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
[TBL] [Abstract][Full Text] [Related]
23. A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer.
Shin SY; Centenera MM; Hodgson JT; Nguyen EV; Butler LM; Daly RJ; Nguyen LK
Front Mol Biosci; 2023; 10():1094321. PubMed ID: 36743211
[TBL] [Abstract][Full Text] [Related]
24. Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?
Huber HJ; McKiernan RG; Prehn JH
J Mol Med (Berl); 2014 Mar; 92(3):227-37. PubMed ID: 24477766
[TBL] [Abstract][Full Text] [Related]
25. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
[TBL] [Abstract][Full Text] [Related]
26. Molecular foundations for personalized therapy in prostate cancer.
Fisher KW; Montironi R; Lopez Beltran A; Moch H; Wang L; Scarpelli M; Williamson SR; Koch MO; Cheng L
Curr Drug Targets; 2015; 16(2):103-14. PubMed ID: 25547910
[TBL] [Abstract][Full Text] [Related]
27. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening.
Pashayan N; Duffy SW; Chowdhury S; Dent T; Burton H; Neal DE; Easton DF; Eeles R; Pharoah P
Br J Cancer; 2011 May; 104(10):1656-63. PubMed ID: 21468051
[TBL] [Abstract][Full Text] [Related]
28. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
[TBL] [Abstract][Full Text] [Related]
29. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology.
Boussios S; Rassy E; Shah S; Ioannidou E; Sheriff M; Pavlidis N
Expert Opin Ther Targets; 2021 May; 25(5):329-333. PubMed ID: 34225539
[No Abstract] [Full Text] [Related]
30. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
[TBL] [Abstract][Full Text] [Related]
31. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.
Ding G; Feng C; Jiang H; Ding Q; Zhang L; Na R; Xu H; Liu J
PLoS One; 2013; 8(10):e77400. PubMed ID: 24130883
[TBL] [Abstract][Full Text] [Related]
32. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
Cao J; Chan WC; Chow MSS
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
[TBL] [Abstract][Full Text] [Related]
33. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
34. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
[TBL] [Abstract][Full Text] [Related]
35. Precision Medicine Approach in Prostate Cancer.
Assadi M; Jokar N; Ghasemi M; Nabipour I; Gholamrezanezhad A; Ahmadzadehfar H
Curr Pharm Des; 2020; 26(31):3783-3798. PubMed ID: 32067601
[TBL] [Abstract][Full Text] [Related]
36. A computational bioinformatics analysis of gene expression identifies candidate agents for prostate cancer.
Wen DY; Geng J; Li W; Guo CC; Zheng JH
Andrologia; 2014 Aug; 46(6):625-32. PubMed ID: 23790256
[TBL] [Abstract][Full Text] [Related]
37. Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.
Albany C; Hahn NM
Asian J Androl; 2014; 16(3):359-63. PubMed ID: 24713836
[TBL] [Abstract][Full Text] [Related]
38. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-β1/focal adhesion kinase/c-Src signaling pathway.
Liu X; Yan Z; Huang L; Guo M; Zhang Z; Guo C
Oncol Rep; 2011 May; 25(5):1343-51. PubMed ID: 21369706
[TBL] [Abstract][Full Text] [Related]
39. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
40. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
Gray PJ; Stevenson MA; Calderwood SK
Cancer Res; 2007 Dec; 67(24):11942-50. PubMed ID: 18089825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
